2022 World Conference on Lung Cancer (ePosters)-EP08.01-051. Clinical Characterization and Outcomes of Non Small Cell Lung Cancer with HER2 Alterations in the Era of Immunotherapy

Pdf Summary

In a recent study conducted at Mayo Clinic, the clinical characteristics and outcomes of non-small-cell lung cancer (NSCLC) patients with HER2 alterations in the era of immunotherapy were examined. The study aimed to determine the efficacy of immunotherapy and compare the outcomes of HER2-altered NSCLC patients to the general NSCLC population.<br /><br />The researchers observed similar efficacy of immunotherapy and clinical outcomes in HER2-altered NSCLC patients compared to the general NSCLC patient population. Both patients with HER2 mutation and amplification responded similarly to immunotherapy. Patients with concurrent TP53 mutation tended to have a prolonged progression-free survival (PFS), while those with KRAS co-mutation had a shorter PFS compared to other HER2-altered NSCLC patients. Additionally, patients with actionable EGFR mutations responded well to EGFR inhibitors.<br /><br />The study was based on a cohort of 50 NSCLC patients with HER2 alterations diagnosed at Mayo Clinic Florida between 2014 and 2021. The tumor molecular alterations were analyzed using next-generation sequencing, and the treatment modalities, PFS, and overall survival (OS) were investigated. The outcomes of these patients were compared to historical data from previous large clinical trials.<br /><br />The most common histology among the HER2-altered NSCLC patients was adenocarcinoma, followed by squamous cell carcinoma. The majority of patients were diagnosed at stage IV. The median PFS and OS for patients receiving chemotherapy as the first-line therapy were 3.9 months and 13.0 months, respectively. Patients receiving immunotherapy as the first-line therapy had a median PFS of 12.5 months and an OS of 19.3 months. Among the stage IV patients, those receiving immunotherapy as the second line had a median PFS of 3.4 months and an OS of 9.3 months. The median OS for all stage IV patients was 14.6 months.<br /><br />In conclusion, this study found that HER2-altered NSCLC patients had similar efficacy of immunotherapy and clinical outcomes compared to the general NSCLC population. Patients with concurrent TP53 or KRAS mutations had different PFS outcomes, while patients with actionable EGFR mutations responded well to EGFR inhibitors. Further studies with larger datasets are needed to validate these findings.

Asset Subtitle

Shenduo Li

Meta Tag

Speaker Shenduo Li

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Mayo Clinic

non-small-cell lung cancer

NSCLC

HER2 alterations

immunotherapy

clinical characteristics

outcomes

efficacy

TP53 mutation

KRAS co-mutation